Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: molemania who wrote (288)	11/4/1997 8:39:00 AM
From: NeuroInvestment	Read Replies (1) \| Respond to of 675

CNSI is not 'going under' in the usual colloquial sense of the term, not with 34.3 million in cash. Your other two hypotheses are likely both pertinent. There are massive losses to be taken by investors who have (in many cases) massive gains elsewhere to be offset. But there is also indifference mixed with disillusionment: instead of having a drug approaching the market in 2 major indications, CNSI is essentially now an early-stage company just barely into Phase I for CNS 5161, still in preclinical for GGF. That is the kind of setback, and resetting of investor expectations, that I expect will leave the stock in the doldrums for the foreseeable future. Fluctuations may occur based on intermittent rumors of 'buyout', but that is more akin to gambling than investing. NeuroInvestment